Literature DB >> 30682219

Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy.

Isabell Brikell1, Qi Chen1, Ralf Kuja-Halkola1, Brian M D'Onofrio1,2, Kelsey K Wiggs2, Paul Lichtenstein1, Catarina Almqvist1,3, Patrick D Quinn2, Zheng Chang1, Henrik Larsson1,4.   

Abstract

OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) affects 10%-30% of individuals with epilepsy, yet concerns remain regarding the safety of ADHD medication in this group. The objective of this study was to examine the risk of acute seizures associated with ADHD medication in individuals with epilepsy.
METHODS: A total of 21 557 individuals with a seizure history born between 1987 and 2003 were identified from Swedish population registers. Within this study population, we also identified 6773 youth (<19 years of age) who meet criteria for epilepsy, and 1605 youth with continuous antiepileptic drug (AED) treatment. ADHD medication initiation and repeated medication periods were identified from the Swedish Prescribed Drug Register between January 1, 2006 and December 31, 2013. Acute seizures were identified via unplanned visits to hospital or specialist care with a primary seizure discharge diagnosis in the Swedish National Patient Register during the same period. Conditional Poisson regression was used to compare the seizure rate during the 24 weeks before and after initiation of ADHD medication with the rate during the same 48 weeks in the previous year. Cox regression was used to compare the seizure rate during ADHD medication periods with the rate during nonmedication periods. Comparisons were made within-individual to adjust for unmeasured, time?constant confounding.
RESULTS: Among 995 individuals who initiated ADHD medication during follow-up, within-individual analyses showed no statistically significant difference in the rate of seizures during the 24 weeks before and after medication initiation, compared to the same period in the previous year. In the full study population 11 754 seizure events occurred during 136 846 person-years and 1855 individuals had at least one ADHD medication period. ADHD medication periods were associated with a reduced rate of acute seizures (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.57-0.94), compared to nonmedication periods within the same individual. Similar associations were found in youth with epilepsy and continuous AED treatment, when adjusting for AEDs, and across sex, age, and comorbid neurodevelopmental disorders. SIGNIFICANCE: We found no evidence for an overall increased rate of acute seizures associated with ADHD medication treatment among individuals with epilepsy. These results suggest that epilepsy should not automatically preclude patients from receiving ADHD medications. Wiley Periodicals, Inc.
© 2019 International League Against Epilepsy.

Entities:  

Keywords:  zzm321990ADHDzzm321990; epilepsy; methylphenidate; neurodevelopmental disorders; pharmacoepidemiology; seizures; treatment

Mesh:

Substances:

Year:  2019        PMID: 30682219      PMCID: PMC6365170          DOI: 10.1111/epi.14640

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  40 in total

1.  Stimulant therapy and seizure risk in children with ADHD.

Authors:  S A Hemmer; J F Pasternak; S G Zecker; B L Trommer
Journal:  Pediatr Neurol       Date:  2001-02       Impact factor: 3.372

2.  The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months.

Authors:  Björn Wettermark; Niklas Hammar; Carl Michael Fored; C MichaelFored; Andrejs Leimanis; Petra Otterblad Olausson; Ulf Bergman; Ingemar Persson; Anders Sundström; Barbro Westerholm; Måns Rosén
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-07       Impact factor: 2.890

3.  Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial.

Authors:  C M van der Feltz-Cornelis; A P Aldenkamp
Journal:  Epilepsy Behav       Date:  2006-02-28       Impact factor: 2.937

4.  Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy.

Authors:  Joseph Gonzalez-Heydrich; Jane Whitney; Deborah Waber; Peter Forbes; Olivia Hsin; Stephen V Faraone; Alice Dodds; Sneha Rao; Christine Mrakotsky; Carlene Macmillan; David R Demaso; Carl de Moor; Alcy Torres; Blaise Bourgeois; Joseph Biederman
Journal:  Epilepsy Behav       Date:  2010-05-21       Impact factor: 2.937

5.  Methylphenidate and seizure frequency in brain injured patients with seizure disorders.

Authors:  B A Wroblewski; J M Leary; A M Phelan; J Whyte; K Manning
Journal:  J Clin Psychiatry       Date:  1992-03       Impact factor: 4.384

6.  The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database.

Authors:  Andrew T McAfee; Karen C Holdridge; Catherine B Johannes; Kenneth Hornbuckle; Alexander M Walker
Journal:  Curr Drug Saf       Date:  2008-05

7.  Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.

Authors:  Joachim F Wernicke; Karen Chilcott Holdridge; Ling Jin; Timothy Edison; Shuyu Zhang; Mark E Bangs; Albert J Allen; Susan Ball; David Dunn
Journal:  Dev Med Child Neurol       Date:  2007-07       Impact factor: 5.449

8.  Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities.

Authors:  Kivilcim Gucuyener; A Kemal Erdemoglu; Selahattin Senol; Ayşe Serdaroglu; Sebnem Soysal; A Ilden Kockar
Journal:  J Child Neurol       Date:  2003-02       Impact factor: 1.987

9.  Validation of epilepsy diagnoses in the Danish National Hospital Register.

Authors:  Jakob Christensen; Mogens Vestergaard; Jørn Olsen; Per Sidenius
Journal:  Epilepsy Res       Date:  2007-07-10       Impact factor: 3.045

10.  Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients.

Authors:  P Mattsson; T Tomson; O Eriksson; L Brännström; G Ringbäck Weitoft
Journal:  Neurology       Date:  2010-01-26       Impact factor: 9.910

View more
  7 in total

Review 1.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

Review 2.  Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma.

Authors:  Rita C Crooms; Margaret O Johnson; Heather Leeper; Ambereen Mehta; Michelle McWhirter; Akanksha Sharma
Journal:  Curr Oncol Rep       Date:  2022-02-22       Impact factor: 5.075

3.  Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders.

Authors:  Laura Ghirardi; Qi Chen; Zheng Chang; Ralf Kuja-Halkola; Charlotte Skoglund; Patrick D Quinn; Brian M D'Onofrio; Henrik Larsson
Journal:  J Child Psychol Psychiatry       Date:  2019-10-18       Impact factor: 8.982

Review 4.  Psychiatric Comorbidities in People With Epilepsy.

Authors:  Marco Mula; Andres M Kanner; Nathalie Jetté; Josemir W Sander
Journal:  Neurol Clin Pract       Date:  2021-04

Review 5.  Do Psychotropic Drugs Cause Epileptic Seizures? A Review of the Available Evidence.

Authors:  Kamil Detyniecki
Journal:  Curr Top Behav Neurosci       Date:  2022

6.  Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study.

Authors:  Vincent Chin-Hung Chen; Yao-Hsu Yang; Charles Tzu-Chi Lee; Yi-Lung Chen; Michael E Dewey; Michael Gossop
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-01-02       Impact factor: 4.785

Review 7.  Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.

Authors:  Beth A Leeman-Markowski; Jesse Adams; Samantha P Martin; Orrin Devinsky; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2020-12-24       Impact factor: 2.937

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.